The utility of prostate‐specific antigen in the management of advanced prostate cancer

To review current prostate‐specific antigen (PSA) metrics used in monitoring treatment of advanced prostate cancer, with a specific focus on castration‐resistant prostate cancer (CRPC) therapies. Explore what is known about the correlation between PSA and androgen levels as well as underlying reasons for persistent PSA expression and serum elevation in CRPC, and outline suggestions for use of PSA in managing patients with advanced prostate cancer. A comprehensive search of the PubMed database for English language articles through April 2012 was performed using the following Medical Subject Headings (MeSH) keywords or terms, alone or in combination: ‘prostate cancer’; ‘prostate cancer treatment’; ‘prostate cancer outcomes’; ‘prostate‐specific antigen’; ‘androgen receptor’; ‘advanced prostate cancer’; ‘castration‐resistant prostate cancer’; ‘biomarkers’. Bibliographies of relevant articles were searched for additional references. Relevant medical society and regulatory agency web sites from the USA and Europe were accessed for issued guidance on PSA use. PSA doubling time (PSADT) is a useful metric for determining which patients should be considered for androgen‐deprivation therapy (ADT) after failing local treatment or for second‐line therapies after failing ADT. However, it is not a validated surrogate for survival and no therapy has received regulatory approval based upon PSADT characteristics. PSA nadir and time‐to‐nadir have been identified as possible prognostic markers for patients receiving ADT. There is no universally accepted definition for PSA progression, nor is PSA progression a regulatory‐approved surrogate for clinical progression in drug approval trials. PSA responses to second‐line therapies can vary and are not considered by regulatory agencies as valid surrogates for clinical endpoints, so they must be assessed in the context of each individual therapy and trial design. PSA expression in CRPC is often a reflection of persistent androgen receptor activity. While we can provide guidance for use of PSA monitoring in managing patients with advanced prostate cancer based on the data at hand, there is an urgent need for prospective analyses of refined PSA metrics in conjunction with newer prostate cancer biomarkers in clinical trials to provide stronger evidence for their roles as surrogate endpoints.

[1]  M. Lucia,et al.  Role of testosterone in managing advanced prostate cancer. , 2012, Urology.

[2]  M. Carducci,et al.  Contemporary experience with ketoconazole in patients with metastatic castration‐resistant prostate cancer: Clinical factors associated with PSA response and disease progression , 2012, The Prostate.

[3]  D. Altman,et al.  The basis for monitoring strategies in clinical guidelines: a case study of prostate-specific antigen for monitoring in prostate cancer , 2012, Canadian Medical Association Journal.

[4]  T. Choueiri,et al.  Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy , 2012, The aging male : the official journal of the International Society for the Study of the Aging Male.

[5]  A. D'Amico,et al.  Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials. , 2012, The Lancet. Oncology.

[6]  J. Eastham,et al.  918 Prostate-specific antigen kinetics in patients with bone metastases from castration-resistant prostate cancer receiving zoledronic acid therapy , 2012 .

[7]  C. Parker,et al.  Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer , 2012, Journal of the National Cancer Institute.

[8]  B. Trock,et al.  The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up , 2012, BJU international.

[9]  David C. Miller,et al.  Missing the mark on prostate-specific antigen screening. , 2011, JAMA.

[10]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.

[11]  E. Antonarakis,et al.  The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen Deprivation , 2011, The Prostate.

[12]  T. Wiegel,et al.  [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer]. , 2011, Actas urologicas espanolas.

[13]  H. Yamanaka,et al.  Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy , 2011, Prostate Cancer and Prostatic Diseases.

[14]  E. Basch,et al.  End points and outcomes in castration-resistant prostate cancer: from clinical trials to clinical practice. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Ming-Tsang Wu,et al.  Impact of prostate‐specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen‐deprivation therapy , 2011, The Prostate.

[16]  E. Antonarakis,et al.  Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database , 2011, BJU international.

[17]  P. Schramek,et al.  Editorial Urologische Onkologie , 2011, Wiener Medizinische Wochenschrift.

[18]  E. Small,et al.  Phase II Study of Abiraterone Acetate in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Displaying Bone Flare Discordant with Serologic Response , 2011, Clinical Cancer Research.

[19]  Arturo Molina,et al.  Abiraterone and increased survival in metastatic prostate cancer. , 2011, The New England journal of medicine.

[20]  J. Nelson,et al.  Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration‐resistant nonmetastatic prostate cancer , 2011, Cancer.

[21]  T. Onishi,et al.  Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis , 2011, Prostate Cancer and Prostatic Diseases.

[22]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[23]  C. Robson,et al.  Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer , 2011, Journal of Cancer Research and Clinical Oncology.

[24]  N. Hara,et al.  Serum prostate‐specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu , 2010, The Prostate.

[25]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[26]  Donatello Telesca,et al.  Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[28]  D. Dearnaley,et al.  Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Larson,et al.  Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Kinshuk Jerath,et al.  The Impact of "One-Stop Shopping" on Competitive Store Brand Strategy , 2009 .

[31]  M. Dowsett,et al.  Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Wun-Jae Kim,et al.  Failing to achieve a nadir prostate‐specific antigen after combined androgen blockade: Predictive factors , 2009, International journal of urology : official journal of the Japanese Urological Association.

[33]  K. Owzar,et al.  Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  C. Kwak,et al.  Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer. , 2009, The Journal of urology.

[35]  C. Tangen,et al.  Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  S. Oudard,et al.  Prostate‐specific antigen kinetics in localized and advanced prostate cancer , 2009, BJU international.

[37]  A. D'Amico,et al.  Time to prostate‐specific antigen nadir independently predicts overall survival in patients who have metastatic hormone‐sensitive prostate cancer treated with androgen‐deprivation therapy , 2009, Cancer.

[38]  H. Sandler,et al.  Potential surrogate endpoints for prostate cancer survival: analysis of a phase III randomized trial. , 2009, Journal of the National Cancer Institute.

[39]  Andrew J Vickers,et al.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  F. Schröder,et al.  The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.

[41]  Tomohiko Ichikawa,et al.  Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. , 2008, The Journal of urology.

[42]  Y. Sugimura,et al.  Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade. , 2008, Japanese journal of clinical oncology.

[43]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[44]  P. Nelson,et al.  Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.

[45]  G. Pond,et al.  Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study , 2008, Clinical Cancer Research.

[46]  P. Kantoff,et al.  Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer , 2008, Cancer.

[47]  Susan Halabi,et al.  Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Epstein,et al.  Small Cell Carcinoma of the Prostate: A Morphologic and Immunohistochemical Study of 95 Cases , 2008, The American journal of surgical pathology.

[49]  F. Goldwasser,et al.  Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[50]  I. Tannock,et al.  A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis , 2007, Clinical Cancer Research.

[51]  Elizabeth Garrett-Mayer,et al.  Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  T. Daskivich,et al.  Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy. , 2007, Urology.

[53]  R. Jennrich,et al.  Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals. , 2007, Urology.

[54]  P. Nelson,et al.  Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. , 2007, Cancer research.

[55]  A. D'Amico,et al.  Time to an undetectable prostate‐specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer‐specific mortality , 2007, Cancer.

[56]  Y. Sugimura,et al.  Prostate‐specific antigen half‐life and pretreatment prostate‐specific antigen: Crucial predictors for prostate‐specific antigen trend in delayed‐combined androgen blockade therapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[57]  Nicholas Bruchovsky,et al.  Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. , 2007 .

[58]  O. Nishizawa,et al.  Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate‐specific antigen: A case report , 2007, International journal of urology : official journal of the Japanese Urological Association.

[59]  Y. Mizutani,et al.  Clinical efficacy of alternative antiandrogen therapy in Japanese men with relapsed prostate cancer after first‐line hormonal therapy , 2007, International journal of urology : official journal of the Japanese Urological Association.

[60]  R. Millikan,et al.  Prostate cancer progression in the presence of undetectable or low serum prostate‐specific antigen level , 2007, Cancer.

[61]  P. Nelson,et al.  Persistent intraprostatic androgen concentrations after medical castration in healthy men. , 2006, The Journal of clinical endocrinology and metabolism.

[62]  W. Gerald,et al.  Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. , 2006, Urology.

[63]  S. North,et al.  Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer. , 2006, Urology.

[64]  C. Tangen,et al.  Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  A. D'Amico,et al.  Predictors of mortality after androgen‐deprivation therapy in patients with rapidly rising prostate‐specific antigen levels after local therapy for prostate cancer , 2006, Cancer.

[66]  C. Tangen,et al.  Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. , 2006, Journal of the National Cancer Institute.

[67]  Pankaj K Choudhary,et al.  Critical analysis of prostate‐specific antigen doubling time calculation methodology , 2006, Cancer.

[68]  A. D'Amico,et al.  Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[70]  F. Saad,et al.  Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  L. Dogliotti,et al.  Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.

[72]  D. Ghosh,et al.  Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases , 2004, Cancer Research.

[73]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, New England Journal of Medicine.

[74]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[75]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[76]  J. Morote,et al.  Nadir prostate‐specific antigen best predicts the progression to androgen‐independent prostate cancer , 2004, International journal of cancer.

[77]  J. Schalken,et al.  Molecular and cellular prostate biology: origin of prostate‐specific antigen expression and implications for benign prostatic hyperplasia , 2004, BJU international.

[78]  Ming-Hui Chen,et al.  Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. , 2003, Journal of the National Cancer Institute.

[79]  Sang Eun Lee,et al.  Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. , 2002, The Journal of urology.

[80]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[81]  A. K. Levinson,et al.  Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. , 2000, Journal of Urology.

[82]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[84]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[85]  G. Murphy,et al.  Prostatic‐specific antigen: An immunohistologic marker for prostatic neoplasms , 1981, Cancer.

[86]  J. Eastham,et al.  Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid. , 2014, European Urology.

[87]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. , 2011, European urology.

[88]  Mottet Nicolas,et al.  前立腺癌に関するEAUガイドライン パートII:進行性再発性および性腺摘除抵抗性前立腺癌の治療 , 2011 .

[89]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[90]  H. Bonkhoff,et al.  From pathogenesis to prevention of castration resistant prostate cancer , 2010, The Prostate.

[91]  A. D'Amico,et al.  Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. , 2008, Urology.

[92]  A. D'Amico,et al.  Prostate Specific Antigen Doubling Time , 2008 .

[93]  Nicholas Bruchovsky,et al.  Locally advanced prostate cancer—biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate‐specific antigen recurrence after radiotherapy , 2007, Cancer.

[94]  C. Roehrborn,et al.  Nadir prostate-specific antigen as a predictor of progression to androgen-independent prostate cancer. , 2002, Urology.

[95]  W. A. Soanes,et al.  Precipitating antibody in the sera of patients treated cryosurgically for carcinoma of the prostate. , 1969, Experimental medicine and surgery.